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SUMMARY
GB virus C (GBV-C) is frequently identified in patients co-infected with human
immunodeficiency virus type 1 (HIV-1) due to the similar transmission routes. However,
it remains unclear how these two viruses interact with each other and how one virus affects
the replication of the other in the human body. In this study, we performed a case-control
study to determine whether GBV-C viraemia could prevent the acquisition of HIV-1 infection,
and a cohort study to determine the prevalence, genotypic characteristics and incidence of
GBV-C infection in men who have sex with men (MSM) populations in Beijing, China. The
prevalence of GBV-C infection in HIV-1-negative subjects was similar to that in HIV-1-positive
subjects. Before HIV-1 acquisition, the prevalence of GBV-C was 17.7%, which increased to
27.2% at the acute stage and to 34% at the chronic stage. Genotype 3 was the major genotype
of GBV-C in both groups. A significantly positive correlation was observed between the CD4+
T-cell counts and GBV-C viral loads at the acute stage of HIV infection. At the chronic stage
(12 months later), this correlation was no longer significant, although it was still positive.
Overall, this study demonstrated that pre-existing GBV-C viraemia could not prevent the
acquisition of HIV-1 infection and transmission of HIV-1 significantly increased the prevalence
of GBV-C viraemia.
Key words : Cohort study, GB virus C; human immunodeficiency virus type 1, men who have sex
with men (MSM).
INTRODUCTION
GBV-C is a flavivirus that is closely related to
hepatitis C virus (HCV) [1]. Transmission of GBV-C
via parenteral, sexual, and vertical routes has been
documented, and infection is common in many popu-
lations [2–7]. There are five major genotypes that are
prevalent worldwide [8, 9]. Several studies have re-
ported a strong association between the existence of
GBV-C viraemia and the survival of HIV-infected
patients [7, 10, 11]. However, other studies do not
support this association [12–14]. In fact, two studies
showed that patients co-infected with GBV-C and
HIV-1 had an increased mortality rate [15, 16].
* Authors for correspondence : Dr D. Chen orDr H. Wu, No. 8 Xi
Tou Tiao You An Men Wai, Beijing 100054, P.R. China.
(Email : dexi09@yahoo.com) [D. Chen]
(Email : haow99@gmail.com) [H. Wu]
# These authors contributed equally to this work.
Epidemiol. Infect. (2012), 140, 2199–2209. f Cambridge University Press 2012
doi:10.1017/S0950268812000027
Mechanisms underlying the positive effects on the
progression of HIV infection include decreased ex-
pression of CC chemokine receptor 5 (CCR5) on
CD4+ T cells and direct inhibition of HIV replication
by GBV-C [17, 18]. Recent findings suggest that HIV-
1 patients with active GBV-C infection had a
reduced percentage of T cells positive for
CD38+CD4+, CD38+CD8+, CCR5+CD4+, and
CCR5+CD8+, which might provide a key mechan-
ism involved in the protection conferred by GBV-C
against HIV-1 disease progression [19].
MSM are the second most vulnerable population
for HIV-1 infections after intravenous drug users
in China in recent years. In Beijing, 3.0–4.6% of
MSM were found to be HIV-1 positive [20]. A cross-
sectional study has shown a high prevalence of sexually
transmitted infections and HCV to be present in
HIV-1-positive MSM [21], but the infection rate of
GBV-C in MSM has not been established. Here, we
performed a cohort study to evaluate the prevalence
of GBV-C viraemia in MSM for those with a clear
date of HIV-1 infection and those without HIV-1 in-
fection. We also analysed the association of GBV-C
viraemia, syphilis, HCV and hepatitis B virus (HBV)
with HIV-1 infection in this MSM cohort. Further-
more, we determined the potential effect of GBV-C
viraemia on the progression of HIV-1 disease.
MATERIALS AND METHODS
Study sample
The subjects included in this study were selected
from the participants in the AIDS High Risk Cohort
Programme supported by the Beijing Science &
Technology Committee and the study was approved
by the Ethics Committee of the Beijing Youan
Hospital. A total of 4236 MSM were enrolled in the
study between 2007 and 2010. Written informed con-
sent was obtained from all participants. At 2-month
intervals, HIV-related clinical status was assessed,
an interviewer-administered questionnaire was com-
pleted, and blood samples were obtained for detection
of HIV-1 antibodies and HIV-1 RNA levels by im-
munoassay and RT–PCR (Roche, Sweden), respect-
ively. Of 4236 MSM, 99 subjects who had a clear date
of HIV-1 infection and 175 subjects without HIV-1
infection at the same visit as a control were selected
from the cohort for the case-control study. The
prevalence of GBV-C viraemia and antibodies against
HCV, HBV surface antigen (HBsAg) and syphilis
were compared between individuals with HIV-1 in-
fection and controls without HIV-1 infection. In the
cohort study, 99 HIV-1-positive subjects were de-
tected for GBV-C viraemia at the acute stage of HIV
infection and the chronic stage of HIV-1 infection.
Acute stage is defined as negative HIV p24 antibody
testing by enzyme-linked immunosorbent assay in the
presence of detectable HIV-1 RNA or positive HIV
p24 antibody testing and an evolving (f3 bands
positive) HIV Western blot [22]. Chronic stage is de-
fined as having been infected for at least 6 months
and usually for several years [23]. In our study, we
collected the samples at 12 months post-HIV infec-
tion. CD4+ T-cell counts and HIV-1 viral loads were
also determined at each time point.
RT-PCR for detection of GBV-C RNA
GBV-C RNA was extracted from the samples by
the Qiagen viral RNAMini kit (Qiagen, Germany). A
Superscript First-Strand Synthesis kit (Invitrogen,
USA) was used to create GBV-C complementary
DNAs (cDNAs). Both first- and second-round PCRs
were performed using primers that hybridize to 5k
non-translated regions of GBV-C (GenBank ac-
cession no. NC_001710.1, 31–376 nt and 121–333 nt,
respectively). Primers for the first-round RT–PCR
were GBV-F1 (5k-ACT GGG TGC AAG CCC CAG
AAA CC) and GBV-R1 (5k-CTG GTC CTT GTC
AAC TCG CCG). Primers for the second-round PCR
were GBV-F2 (5k-GTG ATG ACA GGG TTG GTA
GGT CGT) and GBV-R2 (5k-GAC ATT GAA GGG
CGA CGT GGA). PCR products were detected on
1.5% agarose gels containing 0.5 mg/ml of ethidium
bromide. The expected band sizes were 366 and
233 bp for the first- and second-round PCRs, re-
spectively.
Quantification of GBV-C viral load
Absolute quantification requires a standard curve
of known amounts of the amplicon per reaction.
The substrates for standard curve were generated by
subcloning the amplicon in a plasmid (pGEM-T easy,
Promega). A standard curve of the GBV-C NCR
plasmid was quantified using the universal QPCR
method in a 25-ml reaction containing 1r Taqman
Universal PCR Master Mix (Applied Biosystems,
USA), 400 nM of primer gbv-p1 (5k-AGC GCA CGG
TCC ACA GGT GTT-3k), 400 nM of primer gbv-p2
(5k-GAC ATT GAA GGG CGA CGT GGA-3k), and
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200 nM of fluorescent probe gbv-probe (5k-FAM-CCC
TAC CGG TGG GAA TAA GGG CCC GAC
TAMRA-3k) (Invitrogen). Serial tenfold dilutions of
GBV-C NCR plasmid were used to cover a range of
104–107 molecules per reaction. Triplicate reactions
of each dilution were pipetted into a 96-well plate and
amplified in an ABI Prism 7900HT real-time PCR
system (Applied Biosystems) at 50 xC for 30 min and
then 94 xC for 2 min for the inactivation of the AMV
reverse transcription enzyme, followed by 40 cycles of
94 xC for 10 s and 60 xC for 1 min. The data was
analysed with Sequence Detection Systems (SDS)
software (Applied Biosystems).
Determination of nucleotide sequences and GBV-C
genotypes
The 627-bp PCR outer fragments of 5k-UTR were
obtained by the primer pairs of GBV-OF1 (5k-GTG
CAA GCC CCA GAA ACC GAC-3k, 36 nt,
NC_001710.1) and GBV-OR1 (5k-GGG GCG CAA
CAG TTT GTG AGG-3k, 641 nt, NC_001710.1).
Subsequently, the 366-bp PCR products were ob-
tained by primer pairs GBV-F1 and GBV-R1. The
nucleotide sequences were determined using an ABI
PRISM3730 XL Genetic Analyzer (ABI Biosystems,
USA). The sequences were aligned with the se-
quences from reference isolates of GBV-C genotype 1
(U36380), genotype 2 (U44402 and AF081782),
genotype 3 (D90601) and genotype 5 (AY949711)
by Mega software (version 5.0). The phylogenetic
trees were constructed by neighbour-joining as im-
plemented in the software and the evolutionary dis-
tances were computed using the maximum composite
likelihood method.
Statistical analyses
The odds ratios (OR) and 95% confidence intervals
(CI) for the association between the occurrence of
GBV-C viraemia and HIV acquisition was calculated.
The occurrence of GBV-C viraemia between subjects
prior to HIV-1 infection and those after acquisition of
HIV-1 infection were compared by Pearson’s x2 test.
The GBV-C viral loads at two time points were com-
pared by paired Student’s t test. The median of HIV
viral loads and CD4+ T-cell counts between the GBV-
C viraemia group and the GBV-C RNA-negative
group in HIV-1-positive subjects were compared by
Mann–Whitney U test. The relationship between
HIV-1 viral loads and GBV-C viral loads, and CD4+
T-cell counts were evaluated by linear regression
analysis.
RESULTS
HIV-1 acquisition was independent of GBV-C
viraemia
To determine the impact of GBV-C viraemia on
HIV-1 transmission, we followed up 99MSM subjects
before and after they acquired HIV-1. Based on a
cross-sectional analysis, we found that the prevalence
of GBV-C viraemia in these 99 study subjects was
17.7% before HIV-1 infection, which was not sig-
nificantly different from that (12.6%) of the 175
HIV-1-negative subjects (OR 1.36, P=0.29) (Table 1),
indicating that a pre-existing GBV-C infection prob-
ably did not play a significant role in preventing the
acquisition of HIV-1. Similarly, the prevalence of
HBV and HCV in the 99 HIV-1-positive subjects was
not significantly different from that in the 175 HIV-1-
negative subjects (Table 1). In contrast, the prevalence
of syphilis in the 99 HIV-1-positive subjects (20.20%)
was significantly higher than that in the HIV-1-
negative subjects (3.42%, OR 5.89). These results
indicated that HIV-1 acquisition was independent
of the presence of HBV, HCV and GBV-C viraemia,
but was highly associated with the presence of syphilis
in the MSM population in Beijing.
Occurrence of GBV-C viraemia was increased after
HIV-1 acquisition
During follow-up studies, the occurrence of GBV-C
viraemia in the 99 HIV-1-positive subjects increased
from 17.7% prior to HIV-1 acquisition (visit 1) to
27.2% at the time of HIV-1 acquisition (visit 2)
(P=0.09). After 12 months (visit 3), GBV-C RNA
Table 1. Association of HIV-1 co-infection with other
pathogens including HBV, HCV, syphilis and GBV-C
Characteristic
Cases
(n=99)
Controls
(n=175) OR (95% CI)
HBV, n (%) 2 (2.02) 3 (1.71) 1.2 (0.20–7.08)
HCV, n (%) 1 (1.01) 2 (1.14) 0.88 (0.08–9.62)
Syphilis, n (%) 20 (20.20) 6 (3.42) 5.89 (2.45–14.18)
GBV-C
viraemia, n (%)
17 (17.7) 22 (12.6) 1.37 (0.76–2.44)
OR, Odds ratio, CI, confidence interval.
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was still positive in the 27 subjects that were positive
at visit 2. Furthermore, an additional seven subjects
had acquired GBV-C viraemia at visit 3, leading to a
significant increase of GBV-C viraemia occurrence
compared to visit 1 (34.3%, P<0.01). However, for
the HIV-negative subjects, newly acquired GBV-C
viraemia was not observed after 12 months. The
occurrence of GBV-C viraemia was significantly
higher in the HIV-1-positive subjects than in the
HIV-1-negative subjects at visits 2 and 3, respectively
(Fig. 1). For HIV-1-positive subjects at visit 2, the
distribution of GBV-C RNA (27.2%) was similar
with respect to age, HBV, HCV, syphilis co-infection
and HIV-1 subtypes. The baseline clinical character-
istics of 99 MSM with HIV-1 infections are given in
Table 2.
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Fig. 1. The occurrence of GBV-C viraemia in subjects at different stages of HIV infection (n=99) and HIV-negative subjects
(n=175). The x-axis represents the time during which the samples were collected. The y-axis represents the percentage
of GBV-C viraemia. P values represent the statistical analysis between each comparison as shown in the figure. Compared
by Pearson’s x2 test, the significance level was set at 0.05. Visit 1 : before HIV infection; visit 2 : near HIV infection; visit 3 :
12 months post-HIV infection.
Table 2. Baseline clinical characteristics of 99 HIV-positive MSM with or
without GBV-C infection
GBV-C viraemia status
GBV-C positive
(n=27)
GBV-C negative
(n=72) P
Median age (years) 25 (24–31) 30 (24–39) 0.064*
Median days of HIV infection 30 (17–30) 30 (28–46) 0.11*
HIV subtype
CRF01-AE 15/27 (55.6%) 36/72 (50%) 0.62#
B 9/27 (33.3%) 21/72 (29.2%) 0.69#
B/C 3/27 (11.1%) 7/72 (9.7%) 1#
C 0 2/72 (1.4%) 1#
Not detected 0 6/72 (8.3%)
HBsAg positive 1/27 (3.7%) 1/72 (1.39%) 0.47#
Anti-HCV positive 0 1/72 (1.39%) 1#
Syphilis 7/27 (25.9%) 13/72 (18.1%) 0.385#
Median (IQR 25–75%)
(log10 copies/ml)
4.29 (3.69–5.51) 4.83 (3.97–5.58) 0.31*
Median (IQR 25–75%)
CD4 counts (cells/mm3)
423 (361–587) 506 (334–602) 0.46*
MSM, Men who have sex with men; IQR, interquartile range.
* Mann–Whitney test.
# Two-sided Pearson’s x2 test.
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GBV-C genotypes
Following the determination of GBV-C prevalence
in 99 HIV-1-positive and 175 HIV-1-negative sub-
jects, the nucleotide sequences of PCR products were
analysed to determine the GBV-C genotypes. Refer-
ence sequences of four genotypes (1, 2, 3, 5) were
included in this analysis. Of the 34 samples from HIV-
1-positive subjects, 30 (88.2%) were GBV-C genotype
3, while the remaining four (11.8%) were genotype 2
according to comparison with the reference strains
(Fig. 2). Of the 22 samples from HIV-1-negative
subjects, one (4.5%) sample was genotype 2, and 21
(95.5%) samples belonged to genotype 3. The genetic
distances were small between the viruses from HIV-
1-positive subjects and those from HIV-1-negative
subjects (Figs 2, 3). These results indicated that the
majority of GBV-C in MSM in Beijing belonged to
genotype 3. During HIV-1 infection, both genotypes 2
and 3 were transmissible.
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Fig. 2. Phylogenetic tree of 34 GBV-C strains from 34 HIV-infected Chinese MSM subjects (indicated by pt. prefix) based on
the sequences of the 5k-UTR gene (300 bp). The phylogenetic tree was constructed by the neighbour-joining method and the
evolutionary distances were computed using the maximum composite likelihood method of Mega software (version 5.0).
Reference strains of genotypes 1 (U36380), 2 (U44402 and AF081782 from China), 3 (D90601) and 5 (AY949711) were
obtained from GenBank. The scale bar represents 0.5% genetic distance (0.005 substitution per site).
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GBV-C viral loads at the acute and chronic stages
of HIV-1 infection
The GBV-C viral load in each of 26 HIV-1-positive
subjects [one case started antiretroviral therapy
(ART) 3 months after HIV-1 acquisition in the fol-
low-up study and was excluded from the analysis]
at two time points (acute and chronic stages) of HIV
infection were quantified with a real-time PCR.
The GBV-C viral loads at the acute stage of HIV-1
infection ranged from 1.62r103 to 2.82r106 copies/
ml with a median of 5.24 log copies/ml. At 12 months
post-HIV-1 acquisition (chronic stage), the viral
loads ranged from 3.24r103 to 3.80r106 copies/ml
with a median of 5.56 log copies/ml. No significant
difference was found between the GBV-C viral
genotype5.AY949771
genotype1.U36380
genotype2.AY196904
genotype3.D90601
AF081782.China
NG49
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NG15
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Fig. 3. Phylogenetic tree of 22 GBV-C strains from 22 HIV-1-negative MSM subjects (indicated by NG prefix) based on the
sequences of the 5k-UTR gene (300 bp). The phylogenetic tree was constructed by the neighbour-joining method and the
evolutionary distances were computed using the maximum composite likelihood method of Mega software (version 5.0).
Reference strains of genotypes 1 (U36380), 2 (U44402 and AF081782 from China), 3 (D90601) and 5 (AY949711) were
obtained from GenBank. The scale bar represents 0.5% genetic distance (0.005 substitution per site).
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loads at acute stage and those at the chronic stage
(Fig. 4).
Comparison of HIV-1 viral loads and CD4+ T-cell
counts between subjects with and without GBV-C
infection
To evaluate the potential effect of GBV-C co-
infection on the replication of HIV-1, we analysed the
HIV viral loads and CD4+ T-cell counts in the
GBV-C-positive and -negative subjects at the acute
and chronic stages of HIV-1 infection. In the GBV-C
RNA-positive subjects, the median HIV viral load
was 4.29 log copies/ml [25–75%, interquartile range
(IQR) 3.69–5.51], and the median CD4+ T-cell count
was 423 cells/mm3 (IQR 361–587) at the acute stage.
In the GBV-C RNA-negative subjects, the median
viral load was 4.81 log copies/ml (IQR 4.00–5.57),
and the median CD4+ T-cell count was 502 cells/mm3
(IQR 327–622). Statistical analysis showed that both
CD4+ T-cell counts and HIV-1 viral load were not
significantly different between the two groups at the
acute stage of HIV-1 infection (P=0.34, P=0.5, re-
spectively) (Table 2).
In the follow-up study, one case in the GBV-
C-positive group and two cases in the GBV-C-
negative group started ART 3 months after acquiring
HIV-1. Seven cases in the GBV-C-negative group
acquired GBV-C viraemia 12 months post-HIV-1
acquisition. Thus, the case numbers in the GBV-
C-positive and -negative groups became 26 and 63,
respectively. The median of HIV-1 viral load for 26
GBV-C-positive subjects and 63 GBV-C-negative
subjects was 4.65 log10 copies/ml (IQR 3.86–5.03) and
4.41 log10 copies/ml (IQR 3.99–4.97), respectively, at
12 months post-HIV-1 acquisition. Statistical analysis
showed that HIV-1 viral load was not significantly
different between these two groups (P=0.47). The
median CD4+ T-cell counts were 431 cells/mm3
(IQR 281–542) and 435 cells/mm3 (IQR 313–613)
in the GBV-C positive and negative groups, respect-
ively. Statistical analysis showed that there was no
significant difference between CD4+ T-cell counts in
the GBV-C-positive and GBV-C-negative subjects
(P=0.31).
We then conducted a correlation analysis between
GBV-C viral load and HIV-1 viral load or CD4+
T-cell count at the acute or chronic stages of HIV-1
infection. At the acute stage, a significant positive
correlation was observed between the GBV-C viral
load and CD4+ T-cell count (r=0.42, P=0.03)
(Fig. 5). HIV-1 viral load was inversely and not sig-
nificantly correlated with the GBV-C viral load
(r=x0.17, P=0.39). At the chronic stage (12 months
post-HIV-1 acquisition), we performed the same
analyses excluding the ART cases, and found a per-
sistent positive correlation between GBV-C viral
loads and CD4+ T-cell counts at this time point, but
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Fig. 4. Comparison of the GBV-C viral loads at the acute
and chronic stages of HIV infection in HIV-1-positive sub-
jects (n=26, one case started ART 3 months after acquiring
HIV-1 and was excluded from the analysis.). The x-axis
represents the stage of HIV infection, ‘Early’ indicates
the acute stage of HIV infection and ‘Late’ indicates the
chronic stage of HIV infection. The y-axis represents the
GBV-C viral loads (log copies/ml). Evaluated by paired
Student’s t test ; significance level was set at 0.05.
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Fig. 5. Correlation between GBV-C viral loads and CD4+
T-cell counts at the acute stage of HIV-1 infection in ART-
naive Chinese MSM subjects (n=27). The x-axis represents
the GBV-C viral loads (log copies/ml). The y-axis represents
the CD4 cell counts (cells/mm3). The GBV-C viral loads
showed a significant positive correlation (r=0.42, P=0.03)
with the CD4+ T-cell counts. The significance level was set
at 0.05 in the linear regression analysis.
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the correlation was not significant (r=0.09, P=0.67)
(Fig. 6). There was a persistent negative, but not
significant, correlation between GBV-C viral load
and HIV-1 viral load (r=x0.2, P=0.34) (data not
shown) at the chronic stage.
DISCUSSION
Previous studies have shown that GBV-C is prevalent
in haemodialysis patients, commercial blood donors
[24], intravenous drug users [25] and female commer-
cial sex workers [26] in China. To our knowledge, the
current study is the first to describe the prevalence of
GBV-C viraemia in the MSM population with or
without HIV-1 infection in China. The positive rate of
GBV-C viraemia in subjects with HIV-1 infections
was 27.2% (27/99) at the time of HIV-1 acquisition,
which was much higher than that in the HIV-1-nega-
tive subjects (P=0.002). These results are consistent
with previous reports showing that the prevalence of
GBV-C viraemia in HIV-1-positive Americans and
Europeans was higher than in HIV-1-negative sub-
jects [14, 27–29]. Our data also indicate that GBV-C
infection is common in recently infected HIV-1 MSM
populations in Beijing, China.
The purpose of this study was to determine if pre-
existence of GBV-C viraemia confers beneficial effects
for resistance to HIV-1 infection. Our case-control
study showed that the positive rate of GBV-C in the
99 HIV-1-positive subjects prior to acquisition of
HIV-1 infection was not significantly different from
that in HIV-1-negative subjects (P=0.29), suggesting
that the pre-existence of GBV-C viraemia does not
play a significant role in resistance to HIV-1 infection.
These results are consistent with a previous study
showing that the prevalence of GBV-C viraemia in
HIV-uninfected individuals who did and did not ac-
quire HIV was similar in American populations [30].
Our results also showed that after HIV-1 acquisition,
the positive rate of GBV-C significantly increased
(Fig. 1), indicating GBV-C infection may occur con-
currently with HIV-1 acquisition. In the follow-up
study, seven cases acquired GBV-C viraemia among
HIV-1-infected individuals at 12 months post-HIV-1
infection, resulting in an incidence density of 9.7/100
person-years. None of the subjects acquired new
GBV-C viraemia in the HIV-negative group during
this period, indicating the high incidence density of
GBV-C viraemia in the MSM populations with HIV
infection. In our study, the occurrence of syphilis was
high in HIV-1-positive subjects. This result was in
accord with a previous cross-sectional study on MSM
in Beijing [21]. In addition, we did not find a high
prevalence of HCV and HBV in MSM with or with-
out HIV-1 infections.
According to some reports of the past two decades,
the major genotype of GBV-C is genotype 3. Few
virus strains of genotypes 2 and 1 have been reported
in different populations in China [31, 32]. Genotypic
analysis in this study showed that MSM subjects were
mainly infected with the genotype 3 strain of GBV-C
(88.2%). Only four subjects were infected with geno-
type 2 strain and no subjects were infected with
genotype 1 strain. Therefore, we concluded that the
major GBV-C genotype prevalent in the MSM
population was similar to that in other populations in
China. Our results also agree with the viral genotype
prevalent in other Asian countries [32, 34]. We at-
tempted to identify if the genotypes had any effect on
the viral loads of GBV-C. Our results showed that
there was no significant relationship between the
genotype and viral loads of GBV-C (data not
shown). This differs from a previous report [34]
showing that GBV-C viral loads were associated
with genotype. This difference may be due to the small
numbers of genotype 2 in our study or differences in
the progress of HIV-1 within the study population.
Previous studies have shown that GBV-C repli-
cation in peripheral bloodmononuclear cells decreases
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Fig. 6. Correlation between GBV-C viral loads and the
CD4+ T-cell counts at the chronic stage (12 months post-
HIV-1 acquisition) of HIV-1 infection in Chinese MSM
subjects (n=26, one case started ART 3 months after ac-
quiring HIV-1 and was excluded from the analysis). The
correlation was still positive but no longer significant
(r=0.09, P=0.67). The x-axis represents the GBV-C viral
loads (log copies/ml). The y-axis represents the CD4 cell
counts (cells/mm3). The significance level was set at 0.05 in
the linear regression analysis.
2206 Z. Liu and others
the expression of HIV-1 co-receptors (chemokine re-
ceptors CCR5 and CXCR4) on the surface of CD4+
T cells and increases the production of various
chemokines that serve as competitive inhibitors of the
HIV-1 co-receptors [18, 35, 36]. It is known that there
is vigorous viral replication at the acute stage during
the natural history of HIV-1 infection. Thus, we
speculate that there are some complicated interactions
between the two viruses at the acute stage of HIV-1
infection. Our results showed that the GBV-C viral
loads had an ascending trend from the acute
(5.24 log copies/ml) to chronic (5.56 log copies/ml)
stage (Fig. 4). Statistical analysis showed a sustained
negative correlation between the GBV-C viral loads
and HIV-1 viral loads in the acute and chronic stages
of HIV-1 infection. Although, we were unable to
conclude that the lower GBV-C viral loads at the
acute stage of HIV-1 infection was directly caused
by higher HIV-1 viral loads, our results provide
some evidence that an inhibitory interaction between
these two viruses might exist during the period of co-
infection.
Previous studies have suggested that HIV RNA
levels at later time points are better indicators of
long-term disease progression compared to the levels
when HIV-1 was acquired because the viral load
reaches a stable mean or ‘set point ’ around 1 year
post-infection [37, 38]. In this study, both plasma HIV
RNA and the CD4+ T-cell counts did not differ be-
tween GBV-C-positive and GBV-C-negative subjects
at 1 year post-HIV infection. These results indicate
that GBV-C viraemia could not increase CD4+ T-cell
counts or reduce HIV-1 viral load during the 1-year
period following HIV-1 infection. These results also
suggest that there was no significant suppressive effect
by GBV-C on HIV-1 replication in the year following
HIV-1 infection. Williams et al. reported that GBV-C
viraemia was significantly associated with the pro-
longed survival of HIV-positive men 5–6 years post-
HIV-1 infection. However, the survival rate was not
increased 12–18 months post-HIV infection [39].
Thus, a long-term follow-up study should be con-
ducted on this cohort.
The molecular mechanisms by which GBV-C
suppresses the replication of HIV-1 are poorly
understood and the effect of GBV-C viraemia on the
progress of HIV disease is currently controversial.
Several studies have shown that GBV-C viraemia
could assist the elevation of CD4+ T-cell counts
because a positive correlation between GBV-C viral
load and CD4+ T-cell counts was observed [40, 41].
Interestingly, in our study, a significant positive
correlation between CD4+ T-cell counts and GBV-C
viral loads (r=0.42, P=0.03) (Fig. 5) was observed at
the acute stage of HIV-1 infection after 1 year, and the
correlation was still positive but no longer significant
(r=0.09, P=0.67) (Fig. 6). Because GBV-C RNA can
replicate in CD4+ T cells, the decrease of CD4+ T
cells during the course of HIV-1 infection implies a
loss of target cells for GBV-C RNA. This might ex-
plain why the correlation between CD4+ T cells and
GBV-C viral loads was weakened 1 year post-HIV
infection as a consequence of a decrease in CD4+ T-
cell counts. Our study can only reflect on the instance
of male homosexuals who sexually transmit GBV-C,
and does not include bloodborne transmission of
HIV-1. In addition, the period of the current study
is not long enough to observe the loss of GBV-C
viraemia and the effect of sustained GBV-C viraemia
on the progress of HIV/AIDS. In conclusion, this is
the first cohort study, to the best of our knowledge, on
GBV-C co-infection with HIV-1 in the MSM popu-
lation of Beijing, China. Long-term observation is
needed on this cohort to further reveal the correlation
between GBV-C and HIV infection.
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